Mevion Medical Systems Release: First Cancer Patient In Ohio Receives Proton Therapy Treatment

24-year-old woman is treated with the MEVION S250 proton therapy system at University Hospitals’ Seidman Cancer Center

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, the leader in compact proton therapy, is announcing that University Hospitals (UH) in Cleveland used the industry-leading MEVION S250 proton therapy system to treat its first patient, a 24-year-old woman with rhabdomyosarcoma, a rare form of sarcoma. The proton therapy treatment made history by being the first in the state of Ohio.

“Our mission is to make proton therapy accessible to all cancer patients, so we’re thrilled that patients and their families in Ohio will no longer be forced to leave the state in order to receive this life saving treatment.”

The new proton therapy center is located on the main campus of UH, directly between UH Rainbow Babies & Children’s Hospital and UH Seidman Cancer Center, part of the elite National Cancer Institute-designated Case Comprehensive Cancer Center at Case Western Reserve University.

“At UH, we aim to provide the most advanced cancer treatment options, and the addition of our MEVION S250 furthers our commitment to bringing the best cancer care possible to our patients” said Nathan Levitan, MD, president of UH Seidman Cancer Center. “We are particularly excited by the fact that this will be one of the few proton therapy centers in the world to be physically connected to a children’s hospital, so both children and adults will be able to benefit from the unmatched precision of proton therapy.”

Proton therapy is an advanced form of radiation that targets tumors more directly than traditional radiation, potentially limiting damage to surrounding healthy tissue and organs. This makes proton therapy the ideal treatment for tumors in sensitive areas such as near the eye, brain, spine, heart and lungs. The MEVION S250 at UH will be used for clinical research that will further explore the advantages of proton therapy.

Mevion revolutionized cancer treatment by inventing compact proton therapy and installing the world’s first compact proton therapy system in 2013. The MEVION S250 Series provides high-quality treatment and superior clinical performances with a footprint that is less than half the size of the next largest system, capital and operational costs that are the lowest on the market, and industry-leading deployment, clinical ramp-up, beam availability, throughput, and uptime rates.

“Mevion is proud to partner with UH Seidman Cancer Center to open the first proton therapy system in Ohio,” said Joseph K. Jachinowski, president and chief executive officer of Mevion Medical Systems. “Our mission is to make proton therapy accessible to all cancer patients, so we’re thrilled that patients and their families in Ohio will no longer be forced to leave the state in order to receive this life saving treatment.”

The MEVION S250 at UH Seidman Cancer Center is Mevion’s fifth clinically operational system and its third at an NCI-Designated Comprehensive Cancer Center. Mevion proton therapy systems are being installed at more NCI-Designated Cancer Centers than any other proton therapy system and Mevion has more compact systems under contract, installed and treating patients than any other company.

About Mevion Medical Systems

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com.

About the MEVION S250 Series

The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The Series is comprised of:

• MEVION S250, offering highly stable, next-generation volumetric delivery capabilities
• MEVION S250i with HYPERSCAN technology, overcoming pencil beam scanning uncertainties by delivering robust Intensity Modulated Proton Therapy treatment at hyper-speed
• MEVION S250mx, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and guarantee 100 percent facility uptime